Galmed Pharmaceuticals (NASDAQ:GLMD) Shares Pass Above 50 Day Moving Average – Time to Sell?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) shares passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $0.63 and traded as high as $0.6409. Galmed Pharmaceuticals shares last traded at $0.4693, with a volume of 19,967,932 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Galmed Pharmaceuticals currently has an average rating of “Sell”.

Galmed Pharmaceuticals Price Performance

The company has a fifty day moving average of $0.63 and a 200-day moving average of $0.72. The firm has a market capitalization of $2.88 million, a PE ratio of -0.42 and a beta of 0.73.

Institutional Trading of Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Two Sigma Investments LP acquired a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned approximately 1.28% of Galmed Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.